title: The implications of colorectal cancer molecular biology in clinical practice.
abstract: Colorectal cancer (CRC) is the third most common malignancy in the United States. Advances in molecular biology have enhanced the understanding of colorectal carcinogenesis. Approximately 75% of CRCs are sporadic; the rest are hereditary or belong to a familial syndrome. Identification of familial forms of CRC have enabled the development of several models of carcinogenesis and made CRC a well-studied malignancy in terms of molecular pathogenesis. Pathways containing multiple mutations and genetic alterations that play a role in hereditary CRC pathogenesis have been elucidated. Many of the molecular changes seen in these pathways also are involved in the development of sporadic cancers.
authors: Department of Surgery, University of California, Davis, Sacramento, CA 95817, USA.
authors: Hamed
authors: H
authors: Kargozaran
authors: Morton
authors: M
authors: Kahlenberg
authors: Vijay P
authors: VP
authors: Khatri
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D049109:Cell Proliferation; D017024:Chemotherapy, Adjuvant; D043171:Chromosomal Instability; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D008403:Mass Screening; D053842:Microsatellite Instability; D008967:Molecular Biology; D009389:Neovascularization, Pathologic / Q000235:genetics; D049268:Positron-Emission Tomography; D011379:Prognosis; D014057:Tomography, X-Ray Computed; D016212:Transforming Growth Factor beta / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D016212:Transforming Growth Factor beta